siRNA Agent Slashes Lipoprotein(a) Levels

(MedPage Today) -- CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial.
The 400-mg dose cut Lp(a) by 93.9 percentage points compared with placebo from...